ONCOMED LETTERHEADChange in Control and Severance Agreement • March 7th, 2019 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
You and OncoMed Pharmaceuticals, Inc. (the “Company”) are parties to an Amended and Restated Change in Control and Severance Agreement dated October 14, 2015 (the “Change in Control Agreement”), which sets forth, among other things, the terms and conditions of certain severance benefits payable to you in the event of a qualifying termination of your employment. This letter (this “Agreement”) amends and restates the Change in Control Agreement to provide you with additional benefits in the event of certain terminations of your employment. This Agreement supersedes the Change in Control Agreement and any other agreement or policy to which the Company is a party with respect to the cessation of your employment with the Company.
SUBLEASESublease • March 7th, 2019 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS LEASE (“Lease”) is made and entered into as of May 30, 2006 (the “Lease Commencement Date”), by and between SLOUGH REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
ONCOMED LETTERHEADSeparation Agreement • March 7th, 2019 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations
This letter confirms the offer made to you by OncoMed Pharmaceuticals, Inc. (the “Company”) in conjunction with your continued employment and separation from the Company as of December 21, 2018, or such earlier date as either you or the Company terminates your employment (the “Separation Date”). If you sign and return this letter to us by December 12, 2018, it shall become a binding agreement between you and the Company (the “Agreement”), and you will become eligible for the payments and benefits of Paragraphs 2, 3 and 4 of this Agreement. If you do not timely sign and return this Agreement, your employment shall terminate effective December 13, 2018, and you shall receive only those payments and benefits set forth in Paragraph 1.
